Lipella Pharmaceuticals Inc. (LIPO)
NASDAQ: LIPO · IEX Real-Time Price · USD
0.452
-0.005 (-1.09%)
Jul 22, 2024, 9:35 AM EDT - Market open
Lipella Pharmaceuticals Employees
As of December 31, 2023, Lipella Pharmaceuticals had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$68,207
Profits / Employee
-$677,564
Market Cap
3.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | 2 | 40.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xylo Technologies | 84 |
| Fresh2 Group | 75 |
| Avinger | 72 |
| Applied DNA Sciences | 55 |
| Aptevo Therapeutics | 40 |
| Scinai Immunotherapeutics | 31 |
| Enveric Biosciences | 7 |
| Ensysce Biosciences | 7 |
LIPO News
- 9 months ago - FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease - PRNewsWire
- 9 months ago - Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 9 months ago - Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 9 months ago - Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment - Market Watch
- 9 months ago - Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus - PRNewsWire
- 10 months ago - Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology - PRNewsWire
- 1 year ago - Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update - PRNewsWire
- 1 year ago - Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting - PRNewsWire